These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38787268)

  • 1. Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions.
    Borba PB; Lago J; Lago T; Araújo-Pereira M; Queiroz ATL; Barud HS; Carvalho LP; Machado PRL; Carvalho EM; de Oliveira CI
    Pathogens; 2024 May; 13(5):. PubMed ID: 38787268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for American cutaneous and mucocutaneous leishmaniasis.
    Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
    Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
    PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
    Machado PRL; Lago A; Cardoso TM; Magalhaes A; Carvalho LP; Lago T; Carvalho AM; Costa R; Carvalho EM
    Emerg Infect Dis; 2024 Mar; 30(3):510-518. PubMed ID: 38407142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by
    Suprien C; Guimarães LH; de Carvalho LP; Machado PRL
    Pathogens; 2024 Apr; 13(4):. PubMed ID: 38668256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
    Lyra MR; Oliveira LFA; Schubach AO; Sampaio RNR; Rodrigues BC; Hueb M; Cota G; Silva RE; Francesconi F; Pompilio MA; França AO; Amato VS; Souza RM; Oliveira RVC; Valete CM; Pimentel MIF
    Clin Infect Dis; 2023 Aug; 77(4):574-582. PubMed ID: 37100061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM; Ishkhanian S
    Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
    de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
    Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
    Javadi A; Khamesipour A; Ghoorchi M; Bahrami M; Khatami A; Sharifi I; Eskandari SE; Fekri A; Aflatoonian MR; Firooz A
    PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010569. PubMed ID: 35802749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
    Aragão Horoiwa T; Cortez M; Sauter IP; Migotto A; Bandeira CL; Cerize NNP; de Oliveira AM
    Eur J Pharm Sci; 2020 Apr; 147():105295. PubMed ID: 32145429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
    Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL
    Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis.
    Bashir U; Tahir M; Anwar MI; Manzoor F
    Pak J Med Sci; 2019; 35(6):1669-1673. PubMed ID: 31777513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.
    Lago T; Carvalho LP; Nascimento M; Guimarães LH; Lago J; Castellucci L; Carvalho AM; Lago A; Carvalho EM
    Clin Infect Dis; 2021 Sep; 73(6):1020-1026. PubMed ID: 33725723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
    Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
    Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.